The major depressive disorder (MDD) treatment market is expected to grow in the coming years, driven by factors such as increasing awareness about mental health, the rising prevalence of MDD, and the availability of effective treatment options. The market is characterized by the presence of both branded and generic drugs, as well as various forms of therapy such as cognitive-behavioral therapy and electroconvulsive therapy. The growing demand for personalized medicine and the increasing use of technology in mental health care are also expected to drive the market. However, the high cost of treatment, side effects associated with medication, and the social stigma attached to mental health issues may pose challenges to the growth of the market.
North America is expected to be dominant in major Depressive Disorder Treatment Market due to increasing prevalence of MDD in the U.S. For instance, according to National Institute of Mental Health In 2015, an estimated 16.1 million adults aged 18 or elder in the U.S. had at least one major depressive episode in the past year, representing 6.7% of all the U.S. adults. Europe is expected to be the second largest market for major depressive disorder treatment due to rapid approval of new therapies from regulatory bodies. For instance in 2015, Soterix Medical received CE Marking for its new tDCS depressive disorder therapy used for the treatment of MDD.
Key Companies in the Depressive Disorder Treatment Industry:
Eli Lilly and Company
Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. The company is focused on creating innovative medicines in several therapeutic areas, including neuroscience, oncology, immunology, and diabetes. Eli Lilly and Company operates in more than 125 countries worldwide, including the United States, Canada, China, and Japan. In November 2022, Eli Lilly and Company announced positive Phase 3 trial results for a new major depressive disorder treatment, which demonstrated significant improvement in symptoms compared to a placebo.
Allergan
Allergan was founded in 1948 and is headquartered in Dublin, Ireland. The company specializes in developing, manufacturing, and marketing pharmaceutical, biologic, surgical, and regenerative medicine products for patients worldwide. Allergan operates in over 100 countries worldwide, including the United States, Canada, and Europe. In June 2022, Allergan announced the initiation of Phase 3 trials for a new major depressive disorder treatment, which is being developed in collaboration with a Japanese pharmaceutical company.
Alkermes
Alkermes was founded in 1987 and is headquartered in Dublin, Ireland. The company is focused on developing innovative medicines for patients with central nervous system disorders, such as schizophrenia, depression, and addiction. Alkermes operates in the United States, Canada, and Europe. In October 2022, Alkermes announced the initiation of a Phase 3 trial for a new major depressive disorder treatment, which is being developed in collaboration with a global pharmaceutical company.